Lattice Biologics Ltd
Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologics products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. It develops acellular demineralized bone scaffold, a human cortical bone demineralized that are used in various applications in orthopedic, neurological, trauma, oral/maxillofacial, and reconstru… Read more
Market Cap & Net Worth: Lattice Biologics Ltd (LBLTF)
Lattice Biologics Ltd (PINK:LBLTF) has a market capitalization of $12.82K ($12.82K) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #44883 globally and #14171 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lattice Biologics Ltd's stock price $0.00 by its total outstanding shares 128218300 (128.22 Million).
Lattice Biologics Ltd Market Cap History: 2015 to 2025
Lattice Biologics Ltd's market capitalization history from 2015 to 2025. Data shows change from $5.77 Million to $12.82K (-47.66% CAGR).
Lattice Biologics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lattice Biologics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.56x
Lattice Biologics Ltd's market cap is 1.56 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $5.77 Million | $4.19K | -$4.06K | 1377.66x | N/A |
| 2016 | $23.21 Million | $3.78 Million | -$7.85 Million | 6.14x | N/A |
| 2017 | $6.41 Million | $2.74 Million | -$1.52 Million | 2.34x | N/A |
| 2018 | $346.19K | $1.16 Million | -$1.23 Million | 0.30x | N/A |
| 2019 | $2.56 Million | $2.19 Million | -$1.01 Million | 1.17x | N/A |
| 2020 | $3.83 Million | $2.46 Million | -$1.48 Million | 1.56x | N/A |
Competitor Companies of LBLTF by Market Capitalization
Companies near Lattice Biologics Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Lattice Biologics Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Lattice Biologics Ltd Historical Marketcap From 2015 to 2025
Between 2015 and today, Lattice Biologics Ltd's market cap moved from $5.77 Million to $ 12.82K, with a yearly change of -47.66%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $12.82K | 0.00% |
| 2024 | $12.82K | 0.00% |
| 2023 | $12.82K | 0.00% |
| 2022 | $12.82K | -99.29% |
| 2021 | $1.80 Million | -53.18% |
| 2020 | $3.83 Million | +49.50% |
| 2019 | $2.56 Million | +640.74% |
| 2018 | $346.19K | -94.60% |
| 2017 | $6.41 Million | -72.38% |
| 2016 | $23.21 Million | +302.22% |
| 2015 | $5.77 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Lattice Biologics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.82K USD |
| MoneyControl | $12.82K USD |
| MarketWatch | $12.82K USD |
| marketcap.company | $12.82K USD |
| Reuters | $12.82K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.